Endocrine Abstracts

Familial benign hypocalciuric hypercalcaemia (FHH) is a lifelong, benign, inherited condition with slightly increased levels of plasma calcium, low urinary calcium excretion, and normal to moderately elevated plasma parathyroid hormone (PTH). In most cases, FHH (type-1) is caused by inactivating mutations in the gene encoding the calcium sensing receptor (CASR) expressed in the parathyroids and the kidneys. The estimated prevalence of FHH is 1 in 78 000 compared with that of p...

Introduction: The osteoblast derived bone formation marker osteocalcin has been reported to decrease adipose tissue in mice. In elderly men, osteocalcin was reported to correlate inversely with fat mass.Aim: To examine the relationship between osteocalcin and regional fat depots.Method: The Odense Androgen Study is a population-based, cross-sectional study of 779 randomly selected men aged 20–29 years. Total, central, upper ex...

Background: Testosterone replacement therapy in severe hypogonadism is indicated, however, the treatment of late onset hypogonadism (LOH) is debated, especially what the diagnostic criteria should be. In LOH bio-available testosterone probably gives a more accurate index of gonadal status as a diagnostic criterion as it takes SHBG into consideration. SHBG is known to increase with ageing, however, SHBG is also negatively influenced by insulin and visceral adiposity.<p clas...

Background: Birth weight has been associated with low bone mass in later life. Previous studies, however, have relied on self-reported data on birth weight, included select populations, or been of a limited size. Moreover, it is unclear if the association between birth weight and bone mass is be mediated by body weight, lean body mass, or fat mass.Aim: We hypothesize that birth weight is associated with peak bone mass in men independent of current lean b...

Objective: The beneficial effects of testosterone treatment (TT) in men with low normal testosterone levels are debated. Chemokine levels have not previously been evaluated during TT in combination with strength training (ST).Design: A randomized, double-blinded, placebo-controlled study of 6 months TT (gel) in 54 men aged 60–78 years with bioavailable testosterone (BioT) <7.3 nmol/l and waist circumference >94 cm randomized to TT (50–1...